Barosense

company

About

BaroSense develops minimally-invasive therapeutic weight loss procedures, devices and surgical treatments for the obese.

  • 11 - 50

Details

Last Funding Type
Series D
Last Funding Money Raised
$27M
Industries
Biotechnology,Health Care,Medical Device,Therapeutics
Founded date
Jan 1, 2001
Number Of Employee
11 - 50
Operating Status
Active

BaroSense is committed to develop and commercialize novel anti-obesity products that provide a meaningful contribution to this leading healthcare problem facing the United States today. BaroSense was conceived in order to create a safe, simple, effective, and minimally invasive alternative to the surgical treatment of obesity - an innovative approach to assist those people who need help beyond traditional diets, and who wish to avoid extensive, irreversible surgery.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
3
$44.40M
Barosense has raised a total of $44.40M in funding over 2 rounds. Their latest funding was raised on Aug 24, 2009 from a Series D round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Aug 24, 2009 Series D $27M 1 Detail
Dec 5, 2007 Series C $11.20M 1 Detail
Dec 22, 2004 Series B $6.20M 1 Detail

Investors

Number of Lead Investors
Number of Investors
2
Barosense is funded by 2 investors. Invesco and RWI Group are the most recent investors.
Investor Name Lead Investor Funding Round
Invesco Series D
RWI Group Series B